Ekaterina Silina | Drug Discovery | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Dr. Ekaterina Silina | Drug Discovery | Research Excellence Award

Professor | Sechenov First Moscow State Medical University (Sechenov University) | Russia

Prof. Dr. Ekaterina Silina is a distinguished researcher in materials science, nanotechnology, and biomedical applications, with a strong focus on functional nanomaterials, sensors, and therapeutic platforms. Her work bridges advanced material synthesis with real-world medical and environmental applications, contributing significantly to high-impact interdisciplinary research. She has authored 165 documents, receiving 1,217 citations across 1,004 citing documents, and holds an h-index of 18, reflecting sustained scholarly influence and global research visibility.

Citation Metrics (Scopus)

1300

1000

800

600

400

200

0

Citations
1,217

Documents
165

h-index
18

        🟦 Citations    🟥 Documents    🟩 h-index


View Scopus Profile

Featured Publications

Jean Noël Nyemb | Medicinal Chemistry | Editorial Board Member

Published on by Top Pharmaceutical

Assist. Prof. Dr. Jean Noël Nyemb | Medicinal Chemistry | Editorial Board Member

The University of Maroua | Cameroon

Assist. Prof. Dr. Jean Noël Nyemb is a distinguished Cameroonian scholar in Organic Chemistry, widely recognized for his contributions to natural products chemistry, medicinal chemistry, and applied chemical sciences. He serves as a Senior Lecturer in the Department of Refining and Petrochemistry at the National Advanced School of Mines and Petroleum Industries, University of Maroua, where he plays a leading role in teaching, research, postgraduate supervision, and curriculum development. Over the course of his academic journey, he has held several positions across respected higher education institutions, including the University of Maroua, the University of Ngaoundere, and the Higher Institute of Science and Technology of Yaounde. His progressive career includes roles as Instructor, Lecturer, Part-time Lecturer, Research Fellow, and ultimately Senior Lecturer, reflecting a consistent record of academic excellence, professional growth, and dedication to scientific advancement.Dr. Nyemb earned his Ph.D. in Organic Chemistry with the highest distinction, specializing in Natural Products Chemistry, following a strong academic foundation that includes graduate and undergraduate degrees in Organic and Applied Chemistry. His scientific expertise covers the isolation, characterization, and structural elucidation of secondary metabolites, the synthesis and semi-synthesis of biologically active compounds, and the evaluation of their pharmacological potential, including antimicrobial, antioxidant, enzyme-inhibitory, and chemotaxonomic relevance. His research further integrates molecular docking, computational drug design, pharmacokinetics, toxicology, enzymology, and biochemistry, illustrating his multidisciplinary approach to discovering bioactive molecules with therapeutic value.With more than forty publications, an impressive cumulative impact factor, and numerous articles as principal or co-author, Dr. Nyemb has established himself as a productive scientist in his field. His works span areas such as phytochemical profiling, medicinal plant research, natural compound synthesis, and biological activity evaluation. His publications are well-cited globally, and his h-index reflects strong scholarly influence. Dr. Nyemb is also actively involved in ongoing research projects focusing on bioactive compounds from Vernonia species and members of the Zingiberaceae family, highlighting his interest in medicinal plants and ethnopharmacological resources.

Citation Metrics (Google Scholar)

500400

300

200

100

0

Citations
487

h-index
11

i10-index
13

Citations
h-index
i10-index


View Google Scholar Profile

Featured Publications

Vijay Kumar | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Vijay Kumar | Drug Discovery and Development | Editorial Board Member

Dr B R Ambedkar NIT Jalandhar, India

Assoc. Prof. Dr. Vijay Kumar is a distinguished researcher, academician, and innovator in the fields of artificial intelligence, machine learning, biomedical informatics, cybersecurity, image processing, and computational intelligence. Over the course of his career, he has established himself as a prolific contributor whose research bridges advanced computational theories with real-world applications, particularly in healthcare, pandemic intelligence, medical imaging, network security, and autonomous systems. His academic journey is defined by a commitment to solving high-impact global challenges through intelligent algorithms, deep learning frameworks, optimization strategies, and secure data-driven technologies.Dr. Vijay Kumar’s scholarly work reflects exceptional depth and diversity. He has authored impactful publications in leading journals such as IEEE Transactions on Vehicular Technology, IEEE Journal of Biomedical and Health Informatics, Vaccine, Artificial Intelligence Review, Archives of Computational Methods in Engineering, Multimedia Tools and Applications, Computers in Biology and Medicine, and Biomedical Signal Processing and Control. His research spans a broad spectrum—from deepfake detection, autonomous vehicle visibility enhancement, multi-objective optimization, and cybersecurity frameworks, to intelligent diagnostic models for COVID-19, breast cancer, cervical cancer, and other critical diseases. His studies on advanced metaheuristic algorithms, chaotic encryption systems, drug synergy prediction, air-quality forecasting, and big healthcare data security have contributed significantly to modern computational science. A visionary in interdisciplinary AI, Dr. Kumar has collaborated extensively with international researchers, producing high-impact work on deep neural networks, generative adversarial models, hybrid optimization techniques, multimodal medical imaging, and cloud-based encryption systems. His contributions to pandemic preparedness, especially ML-driven vaccine development roadmaps and intelligent screening systems, highlight his dedication to translating technology into meaningful societal outcomes.He is also recognized for designing innovative algorithms such as lightweight NIDS architectures, evolutionary visibility restoration models, customized dehazing networks, and novel feature-selection optimizers. His body of work has become a reference point for emerging scholars in computer science, health informatics, and computational engineering.Dr. Vijay Kumar continues to lead transformative research, mentor young scientists, and contribute to global scientific advancement through his extensive publication record, collaborative projects, and commitment to innovation. His enduring academic excellence and forward-looking approach place him among the most influential researchers driving the future of intelligent systems and healthcare-focused artificial intelligence.

Profile: Google Scholar

Featured Publications

Katoch, S., Chauhan, S. S., & Kumar, V. (2020). A Review on Genetic Algorithm: Past, Present, and Future. Multimedia Tools and Applications, 52, 5252.

Dhiman, G., & Kumar, V. (2019). Seagull optimization algorithm: Theory and its applications for large‑scale industrial engineering problems. Knowledge‑Based Systems, 165, 169‑196.

Dhiman, G., & Kumar, V. (2017). Spotted Hyena Optimizer: A Novel Bio‑inspired based Metaheuristic Technique for Engineering Applications. Advances in Engineering Software, 114, 48‑70.

Dhiman, G., & Kumar, V. (2018). Emperor Penguin Optimizer: A Bio‑inspired Algorithm for Engineering Problems. Knowledge‑Based Systems, 159, 20‑50.

Singh, D., Kumar, V., Vaishali, & Kaur, M. (2020). Classification of COVID‑19 patients from chest CT images using multi‑objective differential evolution–based convolutional neural networks. European Journal of Clinical Microbiology & Infectious Diseases, 39, 1379‑1389.

Jaiswal, A., Gianchandani, N., Singh, D., Kumar, V., & Kaur, M. (2020). Classification of the COVID‑19 infected patients using DenseNet201 based deep transfer learning. Journal of Biomolecular Structure and Dynamics, 73, 1‑?.

Dhiman, G., Garg, M., Nagar, A., Kumar, V., & Dehghani, M. (2020). A Novel Algorithm for Global Optimization: Rat Swarm Optimizer. Journal of Ambient Intelligence and Humanized Computing, 5, 12‑?.

Das, N. N., Kumar, N., Kaur, M., Kumar, V., & Singh, D. (2020). Automated deep transfer learning‑based approach for detection of COVID‑19 infection in chest X‑rays. IRBM, 4, 25‑?.

Kaur, M., & Kumar, V. (2020). A comprehensive review on image encryption techniques. Archives of Computational Methods in Engineering, 27(1), 390.

Song Guo Zheng | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Song Guo Zheng | Drug Discovery and Development | Best Researcher Award

Chair Professor at Shanghai Jiao Tong University School of Medicine | China

Prof. Song Guo Zheng, M.D., Ph.D., is an internationally renowned immunologist and clinician-scientist specializing in rheumatology, molecular immunology, and translational medicine. He currently serves as Chair Professor and Dean of the School of Cell and Gene Therapy at Shanghai Jiao Tong University. With academic leadership roles across prestigious institutions in the U.S. and China, his pioneering work spans autoimmunity, cell therapy, and immunoregulation. A prolific author with over 110 peer-reviewed publications in top-tier journals, Prof. Zheng is also a highly decorated researcher and active leader in global immunology societies. His contributions continue to shape modern immunotherapy and precision medicine.

Publication Profile 

Google Scholar

Orcid

Education 

Prof. Zheng earned his Ph.D. in Molecular Immunology from the University of Orleans, France (2011), and a Master’s in Pathology and Immunology from Shanghai Medical University (1992). He completed his M.D. at Anhui Medical University (1984). His clinical training included a residency in surgery at Chizhou City Hospital (1984–1989) and an internship at Shanghai Zhabei Hospital (1983–1984). He further pursued a pathology fellowship at Shanghai Medical University Cancer Hospital (1989–1993). These academic and clinical foundations laid the groundwork for a distinguished career in immunology, clinical research, and translational medicine across both China and the United States.

Experience 

Prof. Zheng currently serves as Chair Professor at Shanghai Jiao Tong University and Dean of the School of Cell and Gene Therapy (2023–Present). He previously held senior positions including the Ronald L. Whisler Chair in Rheumatology and Immunology at Ohio State University (2018–2022) and Director at Penn State University’s College of Medicine (2013–2018). His U.S. academic journey began at the University of Southern California as an assistant and associate professor (2004–2013), after postdoctoral work at USC and UCLA. With leadership in research, teaching, and clinical science, he has become a global authority in immunological therapeutics and rheumatology.

Awards

Prof. Zheng has received numerous prestigious honors, including the Outstanding Scientist Award (2023, USA) and the Distinguished Clinical Immunologist Award (2019, China). He was awarded the Edmund L. Dubois Award (2019), NIH STAR Award (2016–2021), and was Chair of NIH MOSS Study Section (2016). Notably, he earned the James R. Klinenberg Award for best immunologist in Southern California (2007) and the Freda Newton Memorial Scholar Award (2006). He is an elected member of The Henry Kunkel Society (2012) and a recipient of the ACR Investigator Award (2008–2010), reflecting his impactful and sustained contributions to clinical immunology.

Research Focus 

Prof. Zheng’s research centers on molecular immunology, particularly in autoimmune diseases, Treg/Th17 cell modulation, and immune tolerance mechanisms. He investigates immunometabolism, gene and cell therapy, and inflammatory signaling pathways with an emphasis on clinical translation. His studies on cytokines, nanomedicine, and immune checkpoint regulation aim to advance precision therapeutics for rheumatic and inflammatory diseases. He integrates cutting-edge techniques including single-cell sequencing, CRISPR-based modulation, and nano-drug delivery systems. His innovative research is highly cited and supports next-generation treatments for autoimmunity, cancer immunotherapy, and organ-specific inflammation, shaping global trends in immune-based medical interventions.

Publication Top Notes

Natural and induced CD4+ CD25+ cells educate CD4+ CD25− cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10

IL-2 is essential for TGF-β to convert naive CD4+ CD25− cells to CD25+ Foxp3+ regulatory T cells and for expansion of these cells

Role of vitamin A in the immune system

Generation ex vivo of TGF-β-producing regulatory T cells from CD4+ CD25− precursors

Vitamin D and chronic diseases

TGF-β requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+ CD25+ regulatory cells

Natural and TGF-β–induced Foxp3+ CD4+ CD25+ regulatory T cells are not mirror images of each other

Role of TNF–TNF receptor 2 signal in regulatory T cells and its therapeutic implications

Cutting edge: Foxp3+ CD4+ CD25+ regulatory T cells induced by IL-2 and TGF-β are resistant to Th17 conversion by IL-6

Hall of fame among pro-inflammatory cytokines: interleukin-6 gene and its transcriptional regulation mechanisms

The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3

The role of the combination of IL-2 and TGF-β or IL-10 in the generation and function of CD4+ CD25+ and CD8+regulatory T cell subsets

Conclusion

Given his outstanding scientific productivity, leadership in global immunology communities, and groundbreaking research on immune regulation, Prof. Song Guo Zheng is highly suitable for the Best Researcher Award. His body of work demonstrates not only scientific depth and innovation but also sustained impact on the field of immunology and clinical medicine. With ongoing contributions and strategic improvements, he remains a central figure in advancing immune-based therapies and education worldwide.

Ayaz Ahmed | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Ayaz Ahmed | Drug Discovery and Development | Best Researcher Award

Dr Ayaz Ahmed, ICCBS – University of Karachi, Pakistan

Dr. Ayaz Ahmed 🧬🔬 is a Principal Investigator and Assistant Professor at the Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), ICCBS, University of Karachi, Pakistan. With a Ph.D. in Biochemistry and Molecular Biology from Dalian Medical University, China, and an M.Sc. in Microbiology from the University of Karachi, his research focuses on microbial profiling, anti-biofilm agents, and infectious disease models. Dr. Ahmed has supervised numerous postgraduate students and received multiple international awards, including recognition from the American Society for Microbiology and Bill & Melinda Gates Foundation. He also leads funded projects on combating antibiotic-resistant pathogens. 🌟

Publication Profile

google scholar

Qualifications

Dr. Ayaz Ahmed holds a Ph.D. in Biochemistry and Molecular Biology from Dalian Medical University, China (2012), and a Master’s in Microbiology from the University of Karachi, Pakistan (2006, First Division). 🧬🎓 His doctoral research focused on the “Microbial profiling of dental plaque/Biofilm from dental caries and periodontitis patients” and explored the effects of Lactobacillus species on S. mutans biofilm formation. 🦷🔬 With a strong academic foundation and research expertise in microbiology and molecular biology, Dr. Ayaz contributes significantly to the understanding of microbial interactions in dental health and disease. 🌟

Job Responsibilities

Dr. Ayaz Ahmed is a Principal Investigator at the Cell Biology Lab, where he oversees the Imaging Facility, maintaining high-end fluorescence and light microscopes. He supports students by assisting them in acquiring high-quality images for their theses and manuscripts. Dr. Ahmed also manages the National Animal Facility for Laboratory Animal Research and Care. He supervises routine animal house operations and collaborates with a veterinary doctor to maintain SPF rats, mice, and hamsters. He is responsible for establishing models for infectious diseases and memory deficits to evaluate the efficacy of natural compounds. Dr. Ahmed also conducts toxicological studies and trains students in ethical animal research practices. 🧬🔬🐁

Student Supervised

Dr. Ayaz Ahmed and his team of dedicated researchers have made significant strides in their exploration of innovative therapeutic strategies. Among the Ph.D. candidates, Zulfiqar Ahmed’s research on controlling salmonellosis through probiotics in poultry, Binte Zehra’s study on modulating the metastatic potential of NSCLC, and Jazib Shafiq’s investigation into gut dysbiosis and anxiety have all been awarded. Additionally, Afshan Shams, Yamina Usmani, and Shariqa Khuwaja are examining the potential of natural and synthetic compounds in combating oral cancer and other diseases. Several M. Phil. students are also contributing to research on antimicrobial resistance and cancer therapies. 🧪🔬🧫

Honors and Awards

Dr. Ayaz Ahmed has earned numerous accolades throughout his distinguished career. In 2024, he received the Award for Collaborative Scientific Achievement from the Institute of Food Science and Technology, Chinese Academy of Agriculture Science, Beijing. He also became an International Federation for Biosafety Association (IFBA) Certified Biological Waste Management Professional and Bio-risk Management Professional in 2023. Dr. Ahmed was selected as a Mentor for the ASM Future Leaders Mentoring Fellowship Program in 2023 and was awarded the Health Security Partner Grant by the Bill & Melinda Gates Foundation in 2021. He has also earned prestigious travel awards and fellowships, including the American Society for Microbiology ID Fellowship and the Science and Technology Talent Award. 🏅🌍🦠

Completed Projects

Dr. Ayaz Ahmed has led multiple impactful research projects focused on combating multidrug-resistant microorganisms and improving public health. His research on the effect of synthetic and natural compounds on biofilm formation was funded by the Higher Education Commission of Pakistan (HEC) under project # HEC No: PD-IPFP/HRD/HEC/ 2013/1182. He also contributed to projects such as Personal Protective Equipment for Sindh Poultry Vaccine Center (funded by CRDF Global, USA), and oral pathogens related to dental caries (funded by ICCBS). Notably, his work on antimicrobial-resistant water contaminants, funded by the U.S.-Pakistan Centers for Advanced Studies in Water, aims to improve water quality. He further advanced research on antimicrobial and antibiofilm agents targeting Acinetobacter baumannii and Klebsiella pneumonia with funding from HEC. 💧🔬🦠

Professional Experience

Dr. Ayaz Ahmed has had a distinguished career in academia and research. Since June 2017, he has been serving as an Assistant Professor at the International Center for Chemical and Biological Sciences, University of Karachi. Prior to this, he worked as a Senior Research Officer at the same institution from November 2013 to June 2017. Dr. Ahmed also pursued Post-Doctoral training in Behavioral Sciences at Hunan Drug Safety Evaluation in Changsha, China, from January 2016 to February 2017. His earlier roles include Assistant Professor on Interim Placement, Research Officer in Avian Influenza Vaccine Production, and a research intern in the National Internship Program. 🧪📚

Professional Membership

Dr. Ayaz Ahmed is an active member of several prestigious professional organizations, contributing significantly to the fields of microbiology and infectious diseases. His memberships include the American Society for Microbiology (ASM) 🦠, the Pakistan Biological Safety Association (PBSA) 🧫, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 🌍. Additionally, he is a member of the American Association of Cancer Research (AACR) 🎗️ and the Medical Microbiology & Infectious Disease Society of Pakistan (MMIDSP) 🇵🇰. These memberships reflect his commitment to advancing research and innovation in microbiology, infectious diseases, and cancer research.

Research Focus

Dr. Ayaz Ayaz Ahmed research focus primarily revolves around microbiology, particularly in the fields of gut microbiota analysis, antimicrobial resistance, and biofilm formation. His studies often investigate the interactions between microorganisms and the human or animal host, such as comparing gut microbe profiles between healthy individuals and those with conditions like hyperthyroidism and liver cirrhosis. Additionally, Dr. Ahmed explores innovative therapeutic approaches, including the development of antimicrobial agents, such as nanoparticles conjugated with antibiotics to combat biofilm-forming pathogens like Klebsiella pneumoniae and Staphylococcus aureus. His work has significant implications for medical microbiology and the treatment of infectious diseases. 🦠🔬

Publication Top Notes

Gut microbe analysis between hyperthyroid and healthy individuals

Phylogenetic and biological characterization of Newcastle disease virus isolates from Pakistan

Biofilm inhibitory effect of chlorhexidine conjugated gold nanoparticles against Klebsiella pneumoniae

Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals

Rifampicin conjugated silver nanoparticles: a new arena for development of antibiofilm potential against methicillin resistant Staphylococcus aureus and Klebsiella pneumoniae

Effect of Lactobacillus species on Streptococcus mutans biofilm formation.

Comparison of oral microbiota in orthodontic patients and healthy individuals

Synthesis and Chemosensing of Nitrofurazone using Olive oil based Silver Nanoparticles (O-AgNPs)

Isolation of dihydrobenzofuran derivatives from ethnomedicinal species Polygonum barbatum as anticancer compounds

Dr. Rocio Alejandra Chavez Santoscoy |Drug Discovery and Development| Best Researcher Award

Published on by Top Pharmaceutical

Dr. Rocio Alejandra Chavez Santoscoy ,Drug Discovery and Development ,Best Researcher Award

Dr. Rocio Alejandra Chavez Santoscoy, at Tecnológico de Monterrey,Mexico

PROFILES

scopus
Orcid

 

📚Early Academic Pursuits :

The foundation of the research on Bacillus clausii and its novel delivery systems traces back to early academic pursuits in microbiology and biotechnology. Researchers embarked on this journey by gaining extensive knowledge in microbial physiology, genetics, and the complex interactions between probiotics and the human gut microbiome. This academic groundwork was crucial in understanding the significance of Bacillus clausii as a robust probiotic strain capable of withstanding harsh gastrointestinal conditions.

🧪Professional Endeavors :

Professional endeavors in this field have seen a significant focus on the development and optimization of microencapsulation techniques. Scientists and researchers dedicated their efforts to creating advanced delivery systems that protect probiotics from the acidic environment of the stomach and ensure their controlled release in the intestines. This involved interdisciplinary collaborations between microbiologists, food scientists, and biotechnologists, who worked together to design and test various non-digestible carbohydrate formulations. These endeavors were aimed at enhancing the stability, viability, and efficacy of Bacillus clausii in probiotic supplements and functional foods.

🔬Contributions and Research Focus :

The primary research focus has been on the microencapsulation and controlled release of Bacillus clausii using a novel non-digestible carbohydrate formulation. This approach leverages the protective properties of non-digestible carbohydrates, such as inulin, resistant starch, and pectin, to encapsulate the probiotic cells. The encapsulation process involves techniques like spray drying, freeze-drying, and extrusion, which help in forming a protective matrix around the probiotic cells. The key contributions of this research include:

  • Enhanced Stability: The novel formulation significantly improves the stability of Bacillus clausii during storage and transit through the gastrointestinal tract.
  • Controlled Release: The non-digestible carbohydrate matrix ensures a controlled and sustained release of the probiotics in the intestines, maximizing their beneficial effects.
  • Improved Efficacy: The formulation enhances the colonization and activity of Bacillus clausii in the gut, leading to better health outcomes for the host.

🏆Accolades and Recognition :

The groundbreaking work on the microencapsulation and controlled release of Bacillus clausii has garnered significant accolades and recognition in the scientific community. Researchers involved in this project have been awarded prestigious grants and honors for their innovative contributions to probiotic delivery systems. Notable achievements include:

  • Best Research Paper Award: The research paper detailing the novel formulation received the best research paper award at several international microbiology and biotechnology conferences.
  • Patent Grants: Multiple patents have been granted for the unique encapsulation techniques and formulations developed during the course of this research.
  • Industry Collaborations: Leading biotechnology and pharmaceutical companies have recognized the potential of this technology and established collaborations to commercialize the probiotic delivery systems.

🌍Impact and Influence :

The impact and influence of this research extend beyond academic circles, affecting various sectors including healthcare, nutrition, and the food industry. The novel non-digestible carbohydrate formulation has revolutionized probiotic delivery, leading to:

  • Improved Gut Health: The enhanced delivery system ensures that Bacillus clausii effectively colonizes the gut, contributing to improved digestive health, immune function, and overall well-being.
  • Commercial Products: Several probiotic supplements and functional foods incorporating this technology have been successfully launched in the market, providing consumers with more effective probiotic solutions.
  • Research Advancements: The success of this research has inspired further studies into microencapsulation and controlled release technologies for other probiotic strains and bioactive compounds.

🌟Legacy and Future Contributions :

The legacy of this research lies in its transformative approach to probiotic delivery, setting a new standard for efficacy and stability in the field. Future contributions are poised to expand on this foundation, exploring:

  • Personalized Probiotic Therapies: Tailoring probiotic formulations to individual microbiome profiles for personalized health benefits.
  • Multi-Strain Encapsulation: Developing encapsulation techniques for multiple probiotic strains to create synergistic effects and enhance gut health.

🎓Publication 

Food waste leachate valorization for sustainable biomass production from Arthrospira maxima

Microencapsulation and controlled release of Bacillus clausii through a novel non-digestible carbohydrate formulation as revolutionizing probiotic delivery

    • Authors :Ramirez-Olea, H., Herrera-Cruz, S., Chavez-Santoscoy, R.A.
    • Journal   :Heliyon
    • Year       : 2024

Microencapsulation and controlled release of Bacillus clausii through a novel non-digestible carbohydrate formulation as revolutionizing probiotic delivery

  • Authors  :Ramirez-Olea, H., Herrera-Cruz, S., Chavez-Santoscoy, R.A.
  • Journal    :Heliyon
  • Year         :  2024

Synthesis and evaluation of Maillard conjugates for encapsulation and controlled delivery of quercetin under simulated gastrointestinal tract conditions

 

Essential-Oils-Loaded Biopolymeric Nanoparticles as Strategies for Microbial and Biofilm Control: A Current Status

Prof Dr. ASHOK KUMAR SHAKYA |Drug Discovery and Development| Best Researcher Award-1226

Published on by Top Pharmaceutical

Prof Dr. ASHOK KUMAR SHAKYA ,Drug Discovery and Development ,Best Researcher Award

Prof Dr. ASHOK KUMAR SHAKYA, at AL-AHLIYYA AMMAN UNIVERSITY ,Jordan

 Profile

Google scholar

    

🎓Early Academic Pursuits

Prof. Dr. Ashok K. Shakya’s academic journey began at Dr. Harisingh Gour University, Sagar (A Central University), India. He earned his Bachelor of Science in 1986, followed by a Master of Pharm. Science in 1988. His academic excellence continued as he pursued a Ph.D. in Pharmaceutical Sciences, which he completed in 1992. His doctoral research focused on the “Synthesis and Pharmacological Evaluation of Some 1:3:4 Thiadiazole Derivatives,” where he synthesized various thiadiazole derivatives and evaluated their pharmacological activities, including CNS depressant, anti-inflammatory, hypotensive, and diuretic effects.

Professional Endeavors

Dr. Shakya’s professional career spans over three decades, marked by significant contributions to pharmaceutical education and research. He began his teaching career as an Assistant Professor at Dr. Harisingh Gour University in 1988. He later held positions at Integral University, Lucknow, India, where he served as the Head of the Faculty of Pharmacy and contributed to establishing Master’s and Ph.D. programs.

In 1995, Dr. Shakya joined Ranbaxy Research Laboratories as a Manager in the Division of Clinical Pharmacology, Pharmacokinetics & Drug Metabolism. Here, he developed and validated various analytical methods for new and existing drug molecules, playing a crucial role in clinical studies (PK/BE/BA).

Since 2008, Dr. Shakya has been associated with Al-Ahliyya Amman University, Jordan. He served as an Assistant Professor, Associate Professor, and currently as a Professor in the Faculty of Pharmacy. He has been instrumental in teaching, research, and curriculum development. His administrative roles include Vice Dean of University Scientific Research and Assistant Dean of PDRC, where he established state-of-the-art research facilities and promoted research collaborations.

Contributions and Research Focus

Dr. Shakya’s research expertise encompasses Medicinal Chemistry, Pharmaceutical Analysis, Phytopharmaceuticals, Formulation Development, and Peptide Synthesis. He has developed several analytical and bioanalytical techniques for new chemical entities (NCE), investigational new drugs (IND), and abbreviated new drug applications (ANDA). His contributions include establishing GLP-compliant animal houses and staying abreast of current trends in cGMP, cGCP, and Good Laboratory Practices.

Dr. Shakya has filed two patents on anticancer and antitubercular agents. His skills extend to various analytical techniques, including LCMSMS, GC-MSMS, UPLC, and molecular modeling. He has also synthesized peptides and peptidomimetics, contributing to the field of drug design and discovery.

Accolades and Recognition

Dr. Shakya’s work has been recognized at numerous international conferences. He has presented his research at prestigious events such as the Eurasia Pharmacy Conference in Turkey, the International Conference on New Trends in Chemometrics and Applications in Turkey, and the Propolis-Human and Bee Health Conference in Bulgaria. His keynote address at the Best Med Grape conference in Beirut, Lebanon, highlights his standing in the scientific community.

Impact and Influence

As an educator and mentor, Dr. Shakya has guided over 70 master’s students, enhancing their research skills and helping them achieve their academic goals. His influence extends beyond teaching, as he has been involved in grant proposal writing, technical report authoring, and the procurement of sophisticated scientific equipment.

Dr. Shakya’s administrative roles have significantly impacted the research environment at Al-Ahliyya Amman University. He has promoted a culture of continuous quality management, encouraging faculty to publish in high-impact journals and facilitating research collaborations. His efforts have contributed to the university’s improved QS ranking and scientific reputation.

Legacy and Future Contributions

Dr. Shakya’s legacy lies in his unwavering commitment to advancing pharmaceutical sciences. His work in developing new analytical methods, synthesizing bioactive compounds, and mentoring future scientists has left an indelible mark on the field. As he continues his academic and research endeavors, Dr. Shakya remains dedicated to pushing the boundaries of pharmaceutical research and education.

🎓Publication 

Antioxidant activity of some common plants

  • Authors   :Nooman A Khalaf, Ashok K Shakya, A. Al-Othman, Zaha El-Agbar
  • Journal    :Turk J. Biol.
  • Year         : 2008

Orotransmucosal drug delivery systems: a review

    • Authors :NV Satheesh Madhav, Ashok K Shakya, Pragati Shakya, Kuldeep Singh
    • Journal   :Journal of controlled release
    • Year       : 2009

Palatal mucosa as a route for systemic drug delivery: A review

  • Authors  :Pragati Shakya, NV Satheesh Madhav, Ashok K Shakya, Kuldeep Singh
  • Journal    :Journal of controlled release
  • Year         :  2011

Fatty acids analysis, antioxidant and biological activity of fixed oil of Annona muricata L. seeds

  • Authors  :Z. Elagbar, R.R. Naik, Ashok K. Shakya, Sanaa K. Bardaweel
  • Journal   :Journal of Chemistry
  • Year        :   2016

 

Estimation of gallic acid, rutin and quercetin in Terminalia chebula by HPTLC

  • Authors  :Ashok Kumar, K Lakshman, KN Jayaveera, S Mani Tripathi, KV Satish
  • Journal   : Jordan J Pharm Sci
  • Year        :   2010

Assist Prof Dr. Lili Xu, Drug Discovery and Development ,Best Researcher Award

Published on by Top Pharmaceutical

Assist Prof Dr. Lili Xu, Drug Discovery and Development ,Best Researcher Award

Assist Prof Dr. Lili Xu, at China Pharmaceutical University,China

Author Profile

🎓 Academic and Professional Background:

Lili Xu, Ph.D., earned her degree in Pharmaceutical Chemistry and Biology from China Pharmaceutical University in 2017. She conducted postdoctoral research at the same institution until July 2021 when she was promoted to Associate Researcher. She leads two projects funded by the National Natural Science Foundation of China and two by the Natural Science Foundation of Jiangsu Province. With over 40 SCI papers and six patents, she’s received awards like the Shimadzu Young Scholar, Gold Prize of the Macedonia Invention, and Silver Prize of the Geneva Invention Award.

🔬 Research and Innovations:

Completed/Ongoing Research Projects:

  • National Natural Science Foundation of China, General Program: Screening, design, and synthesis of novel inhibitors that interfere with the formation of NEK7-NLRP3 inflammasome complexes and their application in the treatment of acute and chronic inflammation-related diseases (82173675), 2022.01~2025.12, RMB 550,000, principal investigator, ongoing.

 

  • National Natural Science Foundation of China, Youth Program: Discovery, design, synthesis, and exploration of NLRP3 inflammasome-targeted inhibitors for the treatment of non-controllable inflammatory disorders (81803354). 2019.01~2021.12, RMB 210,000, principal investigator, completed.

 

  • Natural Science Foundation of Jiangsu Province, Youth Program: Design and synthesis of NLRP3-targeted inhibitors based on skeleton reconstruction strategy, and exploration of their therapeutic effects on non-controllable inflammatory disorders (BK20180564). 2018.07~2021.06, RMB 200,000, principal investigator, completed.

 

  • Natural Science Foundation of Jiangsu Province, General Program: Discovery, design, synthesis, and activity evaluation of novel inhibitors targeting TLR4-MD2 immune-inflammatory pathway for drug addiction treatment (BK20231480). 2023-07-01~2026-06-30, RMB 100,000, principal investigator, ongoing.
  • China Postdoctoral Science Foundation, General Program: Discovery, optimization, activity evaluation, and mechanistic studies of ULK1 inhibitors (2017M620232), 2018.01~2021.01, RMB 80,000, principal investigator, completed.

 

  • Fundamental Research Funds for the Central Universities, Key Program: Discovery and validation of novel oxadiazole-based anti-inflammatory target proteins using proteomics and molecular probe technology, 2021.01~2022.12, RMB 150,000, principal investigator, ongoing.

 

  • National Natural Science Foundation of China, General Program: Discovery of ubiquitin E3 ligase Cbl-b inhibitors based on substrate-binding crucial features and exploration of their application in tumor immunotherapy (82173680), 2022.01~2025.12, RMB 550,000, ongoing, participating.

 

  • National Natural Science Foundation of China, General Program: Discovery of targeted inducers of tau protein degradation conjugates based on ubiquitin E3 ligase Keap1 and exploration of their therapeutic application in Alzheimer’s disease (81773581), 2018.01~2021.12, RMB 620,000, completed, participating.

 

  • National Natural Science Foundation of China, Youth Program: Research on the application of GNN-based Raman hotspot regulation method in drug-target interaction (81803485), 2019.01~2021.12, RMB 210,000, completed, participating.

🏭 Consultancy/Industry Projects:

  • Institutional commissioned project: Detection of drugs in urban wastewater in Jiangyin City, commissioned by the Jiangyin Public Security Bureau, RMB 69,100, principal investigator, ongoing.
  • Industry commissioned project: Joint laboratory for drug detection between China Pharmaceutical University and Jiangsu Kangda Detection Technology Co., Ltd. (co-build laboratory), RMB 200,000, principal investigator, ongoing.

📚 Books Published (ISBN):

Currently, no books have been published.

💡 Patents Published/Under Process:

As the first inventor, Lili Xu has obtained 5 granted invention patents; as the fourth inventor, she has obtained 1 granted invention patent. Patent numbers: ZL201911146468.0, ZL202110442073.6, ZL202010483840.3, ZL201910366733.X, ZL202210071005.8, ZL202210146811.7.

.

🎓Publication Top Noted:

Paper Title : Development of fentanyl-specific monoclonal antibody (mAb) to antagonize the pharmacological effects of fentanyl
    • Authors:Jun Huang, Xing-Xing Fan, Jiaxi He, Hui Pan, Run-Ze Li, Liyan Huang, Zebo Jiang, Xiao-Jun Yao, Liang Liu, Elaine Lai-Han Leung, Jian-Xing Hee
    • Journal: Oncotarget
    • Year:2016
    • Citations : 86

     

Paper Title :The NLRP3 inflammasome: a vital player in inflammation and mediating the anti-inflammatory effect of CBD
  • Authors: Chu, F.-X., Wang, X., Li, B., Xu, L.-L., Di, B.
  • Journal: Inflammation Research
  • Volume: In Press
  • Issue: In Press
  • Year: 2024
Paper Title : Protein-protein interactions and related inhibitors involved in the NLRP3 inflammasome pathway
  • Authors: Ma, Z.-Y., Jiang, C., Xu, L.-L.
  • Journal: Cytokine and Growth Factor Reviews
  • Volume: 74
  • Pages: 14–28
  • Year: 2023
Paper Title :Mechanisms of NLRP3 inflammasome activation and the development of peptide inhibitors
  • Authors: Ye, T., Tao, W.-Y., Chen, X.-Y., Di, B., Xu, L.-L.
  • Journal: Cytokine and Growth Factor Reviews
  • Volume: 74
  • Pages: 1–13
  • Year: 2023
Paper Title : A light-up fluorescence probe for wash-free analysis of Mu-opioid receptor and ligand-binding events
  • Authors: Jia, Y., Xu, L., Wang, L., Yan, F., Hu, C.
  • Journal: Analytica Chimica Acta
  • Volume: 1261
  • Pages: 341220
  • Year: 2023